Behavioral and Psychosocial Characteristics of Clients Accessing Services at IHRI
NCT ID: NCT06741319
Last Updated: 2024-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300000 participants
OBSERVATIONAL
2013-07-02
2030-07-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Behavioral and psychosocial information will be collected using validated questionnaires and from data collection forms routinely used when providing services in different service sites of IHRI and the TRC-ARC. The information will be collected anonymously at baseline and at follow-up visits, according to type of services each client receives. Clients at the Thai Red Cross Anonymous Clinic, Thai Red Cross Mobile Health Clinics, Affiliated Health Clinics and Pribta Tangerine Polyclinic will be given an identification number.
Qualitative methods, including focus group discussions (FGD) and in-depth interviews (IDI) will be conducted with clients and healthcare providers to examine the facilitators, barriers, feasibility and acceptability of service implementation.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To describe behavioral and psychosocial characteristics of clients who access services.
2. To understand the effectiveness of the HIV prevention package offered to clients who access services in terms of cost and infections averted
3. To study changes in behavioral and psychosocial characteristics among clients over time
4. To study differences in behavioral and psychosocial characteristics among clients by gender identity, sexual orientation, HIV status, and service sites
5. To assess behavioral and psychosocial factors that influence the willingness to participate in study trials
6. To assess the facilitators, barriers, feasibility and acceptability of and satisfaction with service implementation among clients and healthcare providers under IHRI and TRCARC
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Demographic characteristics
* Gender identity
* Sex assigned at birth
* Age
* Address
* History of study enrollment(s)
Social and sexual behaviors
* Places where clients go for shopping, dining out, exercise, entertainment
* Places where clients meet their sexual partner(s)
* Places where clients obtain condoms and lubricants
* Social networking and other online services clients regularly use and purposes of using
* Lifetime and current sexual practices and condom use
* Number and types of sexual partners
* Self-perceived HIV risk level
* Disclosure of HIV or sexual orientation status
Psychosocial characteristics
* Sexual orientation
* Educational level
* Occupation and income
* Attitude towards and use of HIV testing and sexual health services
* Use of injecting drugs, recreational drugs, and alcohol
Clinical characteristics
* Medical history, including gender dysphoria and hormone therapy
* HIV counseling and testing
* Diagnosis and treatment of sexually transmitted diseases (STD)
* Sample collection information
* Laboratory results
* Gender dysphoria and mental health history
* Body hair pattern
* Bridging therapy
* Fertility and reproductive issues
* Gender transition effects
Referral and linkage to care for HIV-positive clients
* Health insurance scheme
* Initiation and continuation of antiretroviral treatment
Characteristics associated with service implementation
\- Facilitators, barriers, feasibility and acceptability of and satisfaction with service implementation as identified by clients and healthcare providers
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Recommendation1 by counsellor based on:
A) Presence of GD history B) Understanding of risks and benefits of GAHT D) Practice and readiness for gender transition E) Availability of social support F) Ability to take hormones as instructed
3. Verbal informed consent or signed informed consent on file
4. No exclusionary medical conditions
5. Approved by physician
In SRS- and post-SRS cases2
1. Verbal informed consent or signed informed consent on file
2. No exclusionary medical conditions
3. Approved by physician
Exclusion Criteria
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institute of HIV Research and Innovation Foundation, Thailand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Siriporn Nonenoy, BNH,MPH
Role: STUDY_CHAIR
Institute of HIV Research and Innovation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tangerine Clinic, Institute of HIV Research and Innovation
Pathum Wan, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nittaya Phanuphak, MD.,Ph.D.
Role: primary
Rena Janamnuaysook, MBA
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IHRI009
Identifier Type: -
Identifier Source: org_study_id